MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer-Reference-Cited by-同舟云学术

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

Published:2016-05-17 Issue:1 Volume:14 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Gogas Helen,Kotoula Vassiliki,Alexopoulou Zoi,Christodoulou Christos,Kostopoulos Ioannis,Bobos Mattheos,Raptou Georgia,Charalambous Elpida,Tsolaki Eleftheria,Xanthakis Ioannis,Pentheroudakis George,Koutras Angelos,Bafaloukos Dimitrios,Papakostas Pavlos,Aravantinos Gerasimos,Psyrri Amanda,Petraki Kalliopi,Kalogeras Konstantine T.,Pectasides Dimitrios,Fountzilas George

Funder

Roche Hellas SA

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-016-0883-z

Reference48 articles.

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.

2. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16:1340–9.

3. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32.